Weight gain in infants with Pierre Robin sequence

Josip Tomic1, Philipp Metzler1, Andre Alcon2

  • 1Department of Oral and Maxillofacial Surgery, Medical University of Graz, Graz, Austria.

Insights

Infants with Pierre Robin Sequence (PRS) experienced significant weight gain using a modified palatal plate (MPP). This treatment also reduced the need for early airway surgery in these infants.

Area of Science:

  • Craniofacial anomalies
  • Pediatric surgery
  • Neonatal care

Background:

  • Pierre Robin Sequence (PRS) is characterized by micrognathia, glossoptosis, and airway obstruction.
  • Failure to thrive (FTT) is a common complication in infants with PRS.
  • Current management often involves surgical interventions to address airway issues.

Purpose of the Study:

  • To evaluate the efficacy of the modified palatal plate (MPP) in promoting weight gain in infants with PRS.
  • To assess the impact of MPP treatment on the need for surgical airway management.

Main Methods:

  • Retrospective study of 14 infants with isolated and syndromic PRS treated with MPP.
  • Primary outcome: infant weight gain over three months post-birth.
  • Data collected: demographics, comorbidities, genetic testing, and surgical interventions.

Main Results:

  • 86% of infants showed statistically significant weight gain (p < 0.001) within three months.
  • Mean weight increased from 3147g to 4435g.
  • No infants required mandibular distraction or tongue-lip adhesion for airway management; 21% needed tracheotomy.

Conclusions:

  • MPP treatment leads to significant weight gain in PRS infants.
  • MPP may reduce the need for early surgical airway interventions.
  • Accelerated weight gain may influence timing of future surgical procedures.
Abstract

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
627
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
177
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
162
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
194
Signs of Puberty01:27

Signs of Puberty

Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
1.2K